4,6,7a-trihydroxy-5-methoxy-1,8,8,9-tetramethyl-8,9-dihydro-7aH-phenaleno[1,2-b]furan-3,7-dione;(+/-)-isoherqueinone;(+/-)-Isoherqueinon;Isoherqueinon;Herqueinon;Herqueinone o Isoherqueinone;4,6,7a-trihydroxy-5-methoxy-1,8,8,9-tetramethyl-9H-phenaleno[1,2-b]furan-3,7-dione
已证明脱氧, herqueinone和atrovenetin是相同的。根据光谱证据,这些化合物和相关物质已被表征为取代的9-羟基哌嗪酮。通过氧化降解为适当的萘酐以及进一步氧化为硝基古库斯酸,可以证实该结论。已经确定了重要的氧化产物C 15 H 14 O 9 N 2的组成,该产物通过硝酸作用于Atrovenetin而获得。基于该证据和其他证据,阐明了Atrovenetin的组成及其某些转化产物。
Brooks; Morrison, Journal of the Chemical Society. Perkin transactions I, vol. I, p. 1972 421, 430
作者:Brooks、Morrison
DOI:——
日期:——
Combinations of Cholesterol Ester Transfer Protein Inhibitors and HMG COA Reductase Inhibitors for Cardiovascular Indications
申请人:Keller T. Bradley
公开号:US20070203246A1
公开(公告)日:2007-08-30
The present invention provides combinations of cardiovascular therapeutic compounds for the prophylaxis or treatment of cardiovascular disease including hypercholesterolemia, atherosclerosis, or hyperlipidemia. Combinations disclosed include an HMG CoA reductase inhibitor combined with a cholesteryl ester transfer protein (CETP) inhibitor.
[EN] COMBINATIONS COMPRISING (S)-AMLODIPINE AND A CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITOR, AND METHODS FOR REDUCING HYPERTENSION<br/>[FR] COMBINAISONS COMPRENANT (S)-AMLODIPINE ET UN INHIBITEUR DE LA PROTEINE DE TRANSFERT DE L'ESTER DE CHOLESTERYLE, ET METHODES PERMETTANT DE REDUIRE L'HYPERTENSION
申请人:SEPRACOR INC
公开号:WO2005117869A1
公开(公告)日:2005-12-15
One aspect of the present invention relates to pharmaceutical compositions comprising optically pure (S)-amlodipine and a cholesteryl ester transfer protein inhibitor. In certain embodiments, the cholesteryl ester transfer protein is torcetrapib, JTT-705, or SC-795. In a preferred embodiment, the cholesteryl ester transfer protein is torcetrapib. In certain embodiments, said optically pure (S)-amlodipine is optically pure (S)-amlodipine malate, or a polymorph, pseudopolymorph or solvate thereof. Another aspect of the present invention relates to a method of treating a patient suffering from hypertension, hyperlipidemia, or a cardiac disorder, comprising co-administering a therapeutically effective amount of optically pure (S)-amlodipine and a cholesteryl ester transfer protein inhibitor. In certain embodiments, said optically pure (S)-amlodipine is optically pure (S)amlodipine malate, or a polymorph, pseudopolymorph or solvate thereof.
[EN] COMPOSITIONS AND METHODS RELATED TO DISSOLVED OXIDES<br/>[FR] COMPOSITIONS ET PROCÉDÉS ASSOCIÉS À DES OXYDES DISSOUS
申请人:NATURAL EXTRACTION SYS LLC
公开号:WO2021042001A1
公开(公告)日:2021-03-04
Various aspects of this patent document relate to compositions that comprise an anion that is the conjugate base of a hydrophobic molecule that has a pKa, for example, of at least 7 and no greater than 12. These compositions display improved properties when formulated to interact with an organism because the anions carry negative charges that allows them to both dissolve in water-miscible liquids and maximize their surface area. Interaction with an organism results in at least partial conversion of the anion into the hydrophobic molecule after which the hydrophobic molecule partitions out of a water-miscible liquid and into the organism.
Studies in the biochemistry of micro-organisms. 96. The colouring matters of <i>Penicillium herquei</i> Bainier & Sartory